Placeholder

Cautious Capital

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 263.

Product Description

The funding environment for biotech and start-up companies has improved considerably during the past few years. But venture capital investors are more cautious and more demanding than ever before.
Venture capital interest in the life-sciences industry, and specifically in biotech companies, is increasing. Yet while more venture capital has become available, investors are exercising caution. They are looking for a combination of a successful development track record in a company management team and technology with high therapeutic and commercial potential, as well as a short road to clinical development.
Health industry companies received a record share of venture capital investment dollars in 2004, leading all other industries and capturing 30.2% of all venture capital funds invested during the year, according to a recent MoneyTree Survey, conducted by PricewaterhouseCoopers, Thomson Venture Economics, and the National Venture Capital Association…

Sidebars:
Venture Capital Financing in Life Sciences
Investments in Health Industries as a Percentage of Venture Capital Dollars
Sound Bites from the Field
PharmaVOICE Reader Survey: Venture Capital

Experts on this Topic
Robert A. Ashley. Chairman, CEO, and President, AmpliMed Corp., Tucson, Ariz.; AmpliMed develops novel drugs for the treatment of cancer. For more information, visit amplimed.com.
Karen Boezi. Cofounder and Managing partner, Thomas, McNerney & Partners, San Francisco; Thomas, McNerney & Partners is a healthcare private equity firm that invests in life-sciences and medical technology companies. For more information, visit tm-partners.com.
Dan Giampuzzi. President and CEO, Gemin X Biotechnologies Inc., Montreal, Canada; Gemin X seeks to discover and develop advanced oncology therapeutics based on the modulation of apoptosis. For more information, visit geminx.com.
Tracy Lefteroff. Global Managing Partner, Life-Sciences Industry Services, PricewaterhouseCoopers, Washington, D.C.; PWC provides industry-focused assurance, tax, and advisory services for public and private clients. For more information, visit pwc.com.
P. Sherrill Neff. Managing Partner, Quaker BioVentures, Philadelphia.; Quaker BioVentures is a venture capital firm dedicated to investing in life-sciences companies located in the Mid-Atlantic region. For more information, visit quakerbio.com.
Gordon L. Ryerson. Managing Director, Crosstree Capital Partners, Tampa, Fla.; Crosstree Capital is a boutique investment banking firm serving pharmaceutical services companies. For more information, visit crosstreecapital.com.
Scott Salka. CEO, Ambit Biosciences Corp., San Diego; Ambit Biosciences is a privately held biopharmaceutical company developing small-molecule neuroprotectants for the treatment of stroke and other CNS disorders and kinase inhibitors for the treatment of cancers. For more information, visit ambitbio.com.
Bruce E. Seligmann, Ph.D. Founder, Chairman, and Chief Scientific Officer, High Throughput Genomics, Tucson, Ariz.; HTG develops a universal molecular biology-based tool set to improve the drug-discovery process. For more information, visit htgenomics.com.
Raymond Thek. Director and Vice Chairman of the Tech Group, Lowenstein Sandler PC, Roseland, N.J.; Lowenstein Sandler is a law firm. For more information, visit lowenstein.com.
Douglas M. Tucker. Ph.D. CEO, Neurognotsics Inc., Milwaukee; Neurognostics specializes in the early diagnosis and longitudinal assessment of CNS disorders. For more information, visit neurognostics.com.

FEEDBACK